📁Pharma Team / Shared drive

Year-2 revenue plan $580M global (US $410M, EU $130M, RoW $40M). Reflects revised payer ramp and 78% formulary coverage by Q4.

Three indication expansions (2L mCRC, adjuvant breast, pediatric AML). Subcutaneous reformulation gated to 2028 pending Ph1 PK bridging.